Polarean Imaging plc, a commercial-stage medical imaging technology leader in functional Magnetic Resonance Imaging (MRI) of the lungs, announces it has signed an exclusive distribution agreement with DK Healthcare Co., Ltd. (DK Healthcare) for the distribution of Polarean’s Xenon MRI platform in South Korea.

This agreement represents Polarean’s second international distribution partnership, strengthening the Company’s commercial presence across the Asia-Pacific region. Through this partnership, Polarean is strategically positioning its innovative Xenon MRI platform for entry into one of the world’s most advanced medical imaging markets. The Company will collaborate with DK Healthcare to obtain the necessary regulatory clearances ahead of commercial launch in South Korea.

Founded in 1986 and headquartered in Seoul, DK is a leading provider of diagnostic radiology systems and imaging technologies in Korea. And DK Healthcare is one of the affiliates of DK. Through long-standing partnerships with global medical device manufacturers, DK Healthcare has built a reputation for delivering cutting-edge imaging solutions, along with comprehensive technical, clinical, and maintenance support.

Christopher von Jako, PhD, CEO of Polarean, said: “We are delighted to partner with DK Healthcare, one of South Korea’s most respected medical imaging distributors, to expand access to our Xenon MRI platform. South Korea’s strong emphasis on early detection and precision medicine makes it an ideal growth market, and this agreement accelerates our dual-track strategy to grow internationally through high-quality regional partners while our U.S. team continues to drive adoption domestically.”

Joonhyuk Lee, CEO of DK Healthcare, said: “We are excited to introduce Polarean’s Xenon MRI technology to Korea’s leading hospitals and imaging centres. This platform offers clinicians a new dimension in lung function assessment by enabling visualisation of ventilation and gas exchange that was previously impossible with conventional imaging. We believe Xenon MRI will play a vital role in transforming respiratory care in South Korea through enhancing early detection and outcomes for patients with lung cancer, COPD and beyond.”